Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Carcinoma × osimertinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Stage IB-IIIA Non-small Cell Lung Carcinoma 1 Neoplasm Metastasis 1 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1 Carcinoma 1

Interventions

Pemetrexed 3 Carboplatin 3 durvalumab 2 Cisplatin 2 tremelimumab 1 repotrectinib 1 pralsetinib 1 osimertinib 1 brigatinib 1 atezolizumab 1 Surgical Procedures, Operative 1 Paclitaxel 1 Mitomycin 1 Gemcitabine 1 Crizotinib 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04035486 2025-10-10

FLAURA2

AstraZeneca

Phase 3 Active not recruiting

587 enrolled 44 charts 1 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡